COMMUNIQUÉS West-GlobeNewswire

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
20/12/2024
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177 Lu-RAD202 in Breast and Gastric Cancers The Phase 1 First-In-Human study is designed to assess the safety, tolerability [...]
Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH
20/12/2024
In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in 2mg/kg cohort compared to placebo While there was a [...]
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets
20/12/2024
HAMILTON, BERMUDA, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Trading to continue under ticker symbol “CYTOF” No reverse stock split planned Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (OTCQB: CYTOF), a company [...]
Sernova Reschedules its Annual General and Special Meeting of Shareholders to January 10, 2025
20/12/2024
LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a [...]
Aridis Provides Corporate Update
20/12/2024
LOS GATOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC: ARDS) (“Aridis” or the “Company”), a biopharmaceutical company, today announced a corporate update on recent developments. Company [...]
Aspargo Labs Appoints General Managers in Spain and Germany to Drive International Expansion
20/12/2024
NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s most meaningful Rx and OTC medications into [...]
Lowell Farms Inc. Appoints Philippe Faraut as Chief Financial Officer
20/12/2024
SALINAS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Lowell Farms Inc. (the “Company”) (CSE: LOWL; OTCQX: LOWLF), a California-born cannabis company with advanced production capabilities including extraction, [...]
Novo Nordisk A/S - share repurchase programme
20/12/2024
Bagsværd, Denmark, 20 December 2024 – On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April [...]
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
20/12/2024
JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient [...]
Epitopea et Genevant Sciences annoncent une entente de collaboration
19/12/2024
CAMBRIDGE, Royaume-Uni et MONTRÉAL et VANCOUVER, Colombie-Britannique et BÂLE, Suisse, 19 déc. 2024 (GLOBE NEWSWIRE) -- Epitopea, une société transatlantique d’immunothérapies anticancéreuses qui met au point des [...]
Epitopea and Genevant Sciences Announce Collaboration Agreement
19/12/2024
CAMBRIDGE, United Kingdom and MONTREAL and VANCOUVER, British Columbia and BASEL, Switzerland, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the- [...]
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19/12/2024
Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: [...]
Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules
19/12/2024
AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and [...]
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
19/12/2024
- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell [...]
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19/12/2024
Webcast Scheduled for Thursday, January 2 at 4:30 p.m. Eastern CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated contract development and [...]
Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
19/12/2024
Company on track to initiate the Aurora study to evaluate GTX-102 in other Angelman syndrome genotypes and in other age groups in 2025 NOVATO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. ( [...]
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2024
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies [...]
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options
19/12/2024
Budget impact analysis published in the Expert Review of Ophthalmology journal MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences , Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare [...]
Aptose Announces Positive Decision by Nasdaq Hearings Panel
19/12/2024
SAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]

Pages